-
2 weeks ago | 
patientcareonline.com | Raj Chovatiya |Grace Halsey
Flexible dosing in treatment for atopic dermatitis (AD) aims to match use of medications, whether topical, oral, or injectable, with an individual's lifestyle and the person's particular cycle of symptoms, Raj Chovatiya, MD, PhD, MSCI, told his audience at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee. He presented during the session titled, “Dose Flexibility in Adult Atopic Dermatitis” with colleagues Tejesh Patel, MD, and G.
-
2 weeks ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
At the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, Raj Chovatiya, MD, PhD, MSCI, presented “Dose Flexibility in Adult Atopic Dermatitis” alongside Tejesh Patel, MD, and G.
-
1 month ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video,Raj Chovatiya, MD, PhD, discusses the latest findings on the use of topical roflumilast in patients with psoriasis presented at the 2025 Academy of Dermatology Annual Meeting.
-
1 month ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“I introduce the idea of topical non-steroidals very early. I think that when you really try to emphasize the fact that topical steroids were made for certain things and not made for others, it makes that discussion a little easier when you try to introduce some of our newer options,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
1 month ago | 
healio.com | Raj Chovatiya |Erin Michael
Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of Dermatology Annual Meeting. The study assessed the use of the interleukin-23 inhibitor icotrokinra (Protagonist Therapeutics, Johnson & Johnson) in adult and adolescent patients with moderate-to-severe plaque psoriasis.
-
2 months ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“JAK inhibitors have really given us additional options for therapy in the last few years that we didn't have for our patients, particularly oral therapeutics, something that's been lacking in this disease space,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
2 months ago | 
healio.com | Raj Chovatiya |Erin Michael
In this video, Raj Chovatiya, MD, PhD, discusses findings from the phase 2 STRIDE trial presented at this year’s American Academy of Dermatology Annual Meeting. The study assessed the use of ESK-001 (Alumis), an oral tyrosine kinase 2 inhibitor, among patients with moderate-to-severe plaque psoriasis.
-
2 months ago | 
healio.com | Raj Chovatiya |Erin Michael |Carol L. DiBerardino
In this video, Raj Chovatiya, MD, PhD, discusses updates on oral therapies in psoriasis from the American Academy of Dermatology Annual Meeting. “We saw updates largely in the oral therapeutic realm, even more so than the biologic therapeutic realm,” Chovatiya, who is a clinical associate professor for Chicago Medical School at Rosalind Franklin University and assistant clinical professor at George Washington University School of Health Sciences, said.
-
2 months ago | 
dermatologytimes.com | Raj Chovatiya |Kaitlyn Bader
“RAD is one-stop shop for everything happening in education, clinical practice, and research for atopic dermatitis,” said Raj Chovatiya, MD, PhD, MSCI, in an interview with Dermatology Times.
-
2 months ago | 
ajmc.com | Cameron Santoro |Raj Chovatiya
Raj Chovatiya, MD, PhD, MSCI, clinical associate professor of medicine at Rosalind Franklin University Chicago Medical School and founder and director of the Center for Medical Dermatology/Immunology Research, highlights several aspects that distinguish lebrikizumab (Ebglyss; Eli Lilly) from other biologics targeting the IL-4/IL-13 pathway, based on recent data from various studies.
